<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127811</url>
  </required_header>
  <id_info>
    <org_study_id>d5ZTCN100</org_study_id>
    <nct_id>NCT05127811</nct_id>
  </id_info>
  <brief_title>A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Dose Escalation Study of ZN-d5 Monotherapy in Chinese Subjects With Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zentera Therapeutics HK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zentera Therapeutics HK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I dose-escalation, open-label, multicenter study to assess the safety, tolerability,&#xD;
      clinical activity, and pharmacokinetics (PK) of ZN-d5 in Chinese subjects with non-Hodgkin&#xD;
      lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the Phase I dose escalation study of ZN-d5, it is planned that after the starting dose,&#xD;
      subsequent dose assignments will be made by means of a model-assisted design, until the MTD&#xD;
      or RP2D is determined in the Chinese population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">March 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety monitoring</measure>
    <time_frame>until 30 days after the last dose of study drug</time_frame>
    <description>Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>at the end of Cycle 1</time_frame>
    <description>Dose-limiting toxicities (DLTs) observed in DLT evaluable subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effacy Evaluation</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Efficacy as defined by the 2014 Lugano response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Plasma PK parameters of ZN-d5</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-d5</intervention_name>
    <description>BION design</description>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_label>200mg</arm_group_label>
    <arm_group_label>400mg</arm_group_label>
    <arm_group_label>600mg</arm_group_label>
    <arm_group_label>800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. NHL, relapsed from or refractory to at least 2 prior lines of systemic therapy&#xD;
             (excluding radiotherapy and surgery); subjects must have failed or not be candidates&#xD;
             for available standard therapy expected to provide clinical benefit.&#xD;
&#xD;
          2. Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             and agree to use contraception while on study.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status ≤ 1.&#xD;
&#xD;
          4. Adequate blood and other organ function, defined by the following criteria:&#xD;
&#xD;
               1. Neutrophil count (ANC) ≥ 1.0 × 109/L.&#xD;
&#xD;
               2. Platelet count ≥ 75 × 109/L at least 3 days after platelet transfusion (≥ 50 ×&#xD;
                  109/L permitted if the bone marrow is &gt; 50% lymphoma cells).&#xD;
&#xD;
               3. Hemoglobin ≥ 8.0 g/dL.&#xD;
&#xD;
               4. Coagulation parameters ≤ 1.5 × upper limit of normal (ULN).&#xD;
&#xD;
               5. Liver enzymes ≤ 3 × ULN and total bilirubin ≤ 1.5 × ULN.&#xD;
&#xD;
               6. Creatinine clearance ≥ 60 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any of the following prior to start of ZN-d5 treatment:&#xD;
&#xD;
               1. Systemic administration of antineoplastic agents (including investigational&#xD;
                  agents) within the shorter of 28 days or 5 half-lives.&#xD;
&#xD;
               2. Major surgery within 28 days.&#xD;
&#xD;
               3. Radiotherapy within 14 days.&#xD;
&#xD;
               4. Autologous or allogeneic stem cell transplantation within 60 days, or receiving&#xD;
                  immunosuppression for active graft-versus-host disease.&#xD;
&#xD;
               5. Use of strong CYP3A4 inhibitors, P-gp inhibitors or QT prolonging agents within 5&#xD;
                  half-lives, or potent or moderate CYP3A4 inducers within 14 days.&#xD;
&#xD;
          2. Ongoing and clinically significant non-hematologic toxicity related to prior&#xD;
             antineoplastic therapy.&#xD;
&#xD;
          3. Presence of major cardiovascular system diseases (including QTcF &gt; 480 msec).&#xD;
&#xD;
          4. Positive serology for human immunodeficiency virus, hepatitis B, or hepatitis C unless&#xD;
             no detectable hepatitis B or C viral load.&#xD;
&#xD;
          5. Unable to take oral drugs or presence of severe gastrointestinal abnormalities.&#xD;
&#xD;
          6. Active and uncontrolled clinically significant infection.&#xD;
&#xD;
          7. Other active systemic malignancy or other severe, unstable, or poorly controlled acute&#xD;
             or chronic medical conditions.&#xD;
&#xD;
          8. Prior treatment with venetoclax or other BCL-2 inhibitors.&#xD;
&#xD;
          9. Primary or secondary CNS lymphoma.&#xD;
&#xD;
         10. Presence of post-transplant lymphoproliferative disease, Burkitt's lymphoma,&#xD;
             Burkitt-like lymphoma, T lymphoblastic lymphoma and T lymphoblastic acute leukemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BeiJing Cancer Hospital</name>
      <address>
        <city>BeiJing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yan Set University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

